 To accompany that process, the Company will be working with its Consumer Initiated Testing CIT platform supplier to generate online product content to support sales activities in the USA. Leveraging Genetic Technologies core expertise in predictive risk modelling, the Company has also now completed analysis of the early, available genomic and phenotypic data from 1,500 COVID-19 patients. 